Boston, MA 03/27/2014 (wallstreetpr) – Viking Minerals Inc (OTCMKTS:VKML) shares continue to benefit from the hype of medical marijuana. The stock was touching new highs yesterday, changing exceedingly large volume of shares than normal. The $29.92 million market capped company which is of late showing increasing interest in cannabis business, witnessed its shares establish a new 52-week high at $0.15. Trading between $0.12 and $0.15 throughout Wednesday, shares settled at $0.150, up 36.36 percent, and significantly off their double-zero lowest position in the last one year. Having it in mind that cannabis business still lacks stability, investors are wise to do due diligence on Viking Minerals Inc (OTCMKTS:VKML) and similar stocks jumping on marijuana excitement before staking a position.
The business of protecting content copyright on the Web is shaping out to be a rewarding one for RightsCorp Inc (OTCMKTS:STEV). The company which among other services provides anti-piracy monitoring solutions reported recently that its copyrights are growing rapidly, boosting revenue in the process. The company is also inking deals with strategic partners to win it more business and improve its service offering. In the most recent reporting, the company announced earning more than $324,000 in full year 2013, significantly above the $96,565 revenue generated in full year 2012. The difference in 2013 was contributed to by the more than $155,380 generated in the fourth quarter alone. Shares of RightsCorp Inc (OTCMKTS:STEV) jumped up 19.61 percent to settle at $0.28. Earlier on the shares escalated to $0.30, just a few cents shy of 52-week high of $0.35. The previous session was traded on almost three times the normal daily volume.
Even without profits and revenue as in the case of the most recent quarter, Fate Therapeutics Inc (NASDAQ:FATE) seems to be sliding into the zone where investors want it to be. Its attractive product pipeline has meant that even report of a loss and lack of revenue is not keeping traders away from pushing up the stock. The company recently announced fourth quarter loss of 29 cents per share and no revenue, meeting Zacks consensus on earnings, exceeding the $3.51 loss per share noted in the comparable quarter a year ago. Shares of Fate Therapeutics Inc (NASDAQ:FATE) were up 11.64 percent to $12.28 during Wednesday session.
